<DOC>
	<DOCNO>NCT01159457</DOCNO>
	<brief_summary>Celiac disease infection hepatitis B virus ( HBV ) prevalent worldwide carry high morbidity rate . It recently show patient celiac disease often fail develop immunity standard vaccination HBV infancy . In study , evaluate whether second vaccination series different vaccine , Sci-B-Vac , result well immunological response celiac patient . Eligible patient randomize receive 3-dose vaccination series Engerix Sci-B-Vac vaccines.. Rate responder level immunity compare . This study facilitate good protection celiac patient potentially deadly virus .</brief_summary>
	<brief_title>Comparison Engerix B Vaccine Versus Sci-B-Vac Vaccine Celiac Patients</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients 1 year age confirm diagnosis celiac disease characteristic symptom , serology small bowel biopsy . Completion IM HBV vaccine series infancy . HBsAb titer &lt; 10mIU/mL time enrollment . Immunocompromised subject receive medication may modulate suppress immune system ( i.e . azathioprine , 6MP , steroid ) . Inability obtain write informed consent patient ' assent , appropriate maturity age .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Celiac Disease</keyword>
	<keyword>Hepatitis B vaccination</keyword>
</DOC>